John Frazier
Internal Medicine · Bristol, CTNPI 1235222506
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 226 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 21 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,086 and has fallen 97.7% since, to $25 in 2024.
Across 226 payments — averaging $15.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$668
- AbbVie$538
- Amarin Pharma, Inc.$421
- Novo Nordisk$340
- Pfizer$328
- Lilly USA, LLC$231
- plus $917 from 15 others
What the payments were for
- Food & beverage$3,35197%
- Education$913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 40 | $668 |
| AbbVie(2 entities) | 29 | $538 |
| Amarin Pharma, Inc. | 44 | $421 |
| Novo Nordisk | 21 | $340 |
| Pfizer | 20 | $328 |
| Lilly USA, LLC | 13 | $231 |
| Johnson & Johnson | 14 | $183 |
| AstraZeneca | 12 | $163 |
| E.r. Squibb & Sons, L.L.C. | 7 | $105 |
| Merck | 6 | $87 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $65 |
| Sanofi-aventis U.S. LLC | 3 | $59 |
| Eisai Inc. | 3 | $47 |
| Amgen | 2 | $44 |
| Astellas Pharma US Inc | 1 | $40 |
| Esperion Therapeutics, Inc. | 2 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $25 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Circassia Inc. | 1 | $21 |
| Promius Pharma LLC | 1 | $15 |
| Medtronic | 1 | $15 |
How this compares
$3,442 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 25 | $663 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $463 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Bristol
- Steven RyderWestport$3.9M
- Nancy BrownNew Haven$1.6M
- Arthur DecillisMadison$1M
- Charles MontanoCromwell$970K
- Gary BlickNorwalk$683K
- Scott GottliebStamford$508K
- Jeffrey KatzOxford$361K
- Nicholas DainiakBridgeport$352K
- Thomas PellechiGreenwich$196K
- John PriceGlastonbury$188K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.